Press Releases :: BiomX, Inc. (PHGE)

May 24, 2021 6:30am EDT

BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates

May 18, 2021 8:00am EDT

BiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease

May 18, 2021 6:30am EDT

BiomX to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 24, 2021

Apr 20, 2021 7:00am EDT

BiomX to Present at Upcoming April Investor Events

Mar 31, 2021 6:30am EDT

BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Mar 24, 2021 6:30am EDT

BiomX to Report Fourth Quarter and Full Year 2020 Financial Results on March 31, 2021

Mar 02, 2021 7:00am EST

BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin

Mar 01, 2021 7:00am EST

BiomX to Present at Upcoming March Investor Conferences

Feb 02, 2021 6:30am EST

BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy

Jan 04, 2021 6:30am EST

BiomX to Present at Upcoming January Investor Conferences

Previous
1
2
3
4
5
6
7
8
9
10
Next

Investor Contact Information

Company

BiomX, Inc.
22 Einstein St.
Floor 5
Ness Ziona 7414003
Israel
info@biomx.com

Investor Relations

Anat Primovich
Corporate Project Manager
T: +972506977228
anatp@biomx.com